Halozyme Therapeutics (HALO) EBIT Growth (3y) (2013 - 2026)
Halozyme Therapeutics (HALO) EBIT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 16.96% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 38.78% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 69.02% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Halozyme Therapeutics | 9.55 Bn | 9.23 Bn | 297.47 Mn | 50.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.80% |
| Dec 31, 2025 | -48.07% |
| Sep 30, 2025 | 37.79% |
| Jun 30, 2025 | 81.14% |
| Mar 31, 2025 | 23.21% |
| Dec 31, 2024 | 45.88% |
| Sep 30, 2024 | 29.25% |
| Jun 30, 2024 | 8.01% |
| Mar 31, 2024 | 23.49% |
| Dec 31, 2023 | 9.18% |
| Sep 30, 2023 | 29.87% |
| Jun 30, 2023 | 47.30% |
| Mar 31, 2023 | 165.40% |
| Dec 31, 2022 | 62.91% |
| Sep 30, 2022 | 75.38% |
| Jun 30, 2022 | 64.32% |
| Mar 31, 2022 | 194.39% |
| Dec 31, 2021 | 827.64% |
| Sep 30, 2021 | 70.62% |
| Jun 30, 2021 | 87.91% |